• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

North America - Articles and news items

epidermolysis-abeona

Abeona enrols 5th patient in gene therapy Epidermolysis Bullosa trial

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

EB-101 is the company’s lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of…

antibiotics resistance

Antibiotics: resist the resistance

Blog, Z Homepage promo / 15 September 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…

designation-orphan-drug

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD…

cardio-renal-heart-kidney

Vifor Pharma to top cardio-renal care after Galenica completes Relyapsa acquisition

Industry news / 6 September 2016 / Niamh Louise Marriott, Digital Content Producer

The combination of Galenica’s Vifor Pharma business with Relypsa will create a significant player in cardio-renal care in the US and further strength…

SA-ANTIBIOTIC-RESISTANCE

Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two exeporfinium chloride concentration gels (0.5 & 2.0mg/g) and two viscosities (2% and 4%) applied into the nostrils for 5 days…

Featured-Image

Alzheimer’s disease: reviewing the immediate treatment horizon

Blog, Z Homepage promo / 5 September 2016 / Stuart Goodman, Blue Latitude Health

Blue Latitude Health’s Stuart Goodman discusses the latest progress in Alzheimer’s disease research and treatment to find out why a cure remains elusive…

study-roche

Roche’s cancer immunotherapy drug has longer OS vs. chemotherapy

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events were consistent with what has […]

fostamatinib-successful

Rigel’s fostamatinib successfully meets endpoint in chronic ITP trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)…

high-cholesterol

Success for Sanofi and Regeneron’s LDL cholesterol trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo…

dystrophy-fda-grant

FDA grants Santhera $246,000 for muscular dystrophy trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA have granted Santhera an award of $246,000 in support of its ongoing Phase I trial with omigapil (callisto) incongenital muscular dystrophy (CMD)…

cohort-trial-sanfilippo

Abeona Therapeutics completes cohort in Sanfilippo syndrome trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The first-in-man clinical trial utilises a single injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death…

PCB liver disease

Intercept’s new PBC liver disease treatment yields successful clinical trials

Industry news / 25 August 2016 / Intercept Pharmaceuticals

The trial evaluated safety and efficacy of ocaliva in PBC patients with an inadequate therapeutic response to, lack of tolerance to, ursodeoxycholic acid…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +